To meet medical needs imposed by HPV infection, several experimental vaccines have been developed and are currently in human clinical trials (Brown et al., 2001; Evans et al., 2001; Harro et al., 2001), and one has been shown to be effective in preventing persistent viral infection (Koutsky et al., 2002). These vaccines are based on virus-like particles (VLPs), which assemble spontaneously when the papillomavirus major capsid protein, L1, is recombinantly expressed either alone or together with L2, the minor capsid protein
